 | Up a level |
Kibel, Adam S., Gleave, Martin, Brookman-May, Sabine D., Kim, Won, Evans, Christopher P., Efstathiou, Eleni, Kantoff, Philip W., Ross, Ashley, Shore, Neal D., Briganti, Alberto, Hadaschik, Boris A., Heidenreich, Axel, Rooney, Oliver Brendan, Tian, Shaozhou Ken, Wetherhold, Lisa, Xu, Weichun, Parsons, J. Kellogg, Yeruva, Kesav and Taplin, Mary-Ellen (2022). PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC). J. Clin. Oncol., 40 (6). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Taplin, Mary-Ellen, Gleave, Martin, Evans, Christopher P., Efstathiou, Eleni, Kantoff, Philip W., Ross, Ashley, Shore, Neal D., Briganti, Alberto, Hadaschik, Boris A., Heidenreich, Axel, Rooney, Oliver Brendan, Tian, Shaozhou Ken, Wetherhold, Lisa, Xu, Weichun, Cheng, Shinta, Brookman-May, Sabine Doris, Lopez-Gitlitz, Angela and Kibel, Adam S. (2020). PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). J. Clin. Oncol., 38 (6). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755